Analysis of Carbamazepine, Oxcarbazepine, Their Impurities, and Non-Labeled Interfering Substances by Stability-indicating UPLC/MS/MS Method: Studying the Method’s Greenness Profile

Abdelrahman, Maha M.; Abdelwahab, Nada S.

doi:10.1007/s10337-018-3623-0

Cited by 6 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the European Pharmacopoeia sets the maximum concentration of an individual impurity at 0.1%, while the United States Pharmacopeia (USP) indicates 0.2% as the maximum limit for any individual impurity and 0.5% as the maximum total limit for all present impurities. 6,7 Occurrences and Cases of Tegretol® Withdrawal Overtime A present investigation done in India demonstrates that carbamazepine tablets of the same brand manufactured by different Indian manufacturers show different but acceptable results for all physicochemical tests. 8 In contrast, another study done in Germany, linked the differences in raw material sources to irregular dissolution behavior and consequently clinical failures of CBZ therapy.…”

mentioning

confidence: 68%

Pharmaceutical and Clinical Assessment of Multi-source Tegretol Sold in Egypt

Amer,

Eldeeb,

Eshra

2023

IJPQA

View full text Add to dashboard Cite

across generic Narrow therapeutic index (NTI) medications compared to brands. However, little attention has been given to possible inequality within the same brand due to transportation and storage conditions, production site, manufacturing condition, and product specification requested by different countries. Market surveys has shown that Egypt is one of the countries suffering from this problem, which consequently augments the need for comparing and evaluating brand products marketed under the same brand name, manufactured in different countries under its own licensing trademark™ and sold in Egypt. This work studies the drug carbamazepine (CBZ) available in Egypt as Tegretol® tablets used as an oral first-line anti-epileptic drug (AED). Objectives: The present work investigate and evaluate the pharmaceutical quality and clinical efficacy of Tegretol®, obtained from Egypt and Saudi Arabia and being marketed and sold in Egypt from 2020 to 21. Methods: In-vitro quality testing included potency and uniformity of content tests performed according to USP 2019 monograph. Dissolution rates were also carried by adopting USP dissolution test for the drug. Studies of stability were adjusted at 25°C/65% RH, 45°C/75% RH and 10°C/15% RH. The clinical efficacy was studied by evaluating the pharmacokinetics parameters and blood sodium level during six months of therapy. Results: Variability between multisource Tegretol® brand products were ensured. Potency results and uniformity of content revealed statistically significant difference between Tegretol® sources. Also, variations in dissolution rates were recognized in both Tegretol® sources when dissolved in HCL/KCL, Acetate and Phosphate Buffer dissolution media. Dissimilarities were obtained for hardness and friability testing. Furthermore, a pharmacokinetically and pharmacodynamically inequivalence was ensured. Hence, hyponatremia was more prominent in patients receiving Saudi Arabian Tegretol® compared to patients taking Egyptian Tegretol®. Conclusion: Interchangeability between multi-source Tegretol brand products should be limited.

show abstract